OncologySolid Tumors

Bispecific Antibodies Beyond Hematology: Solid Tumors Enter the Arena

After conquering blood cancers, bispecifics are now targeting lung, breast, and colorectal cancer

SR-2026-020

EditorMara Voss

CopywritersEditorial Team

Coming Soon

Bispecific Antibodies Beyond Hematology: Solid Tumors Enter the Arena

After conquering blood cancers, bispecifics are now targeting lung, breast, and colorectal cancer

Why We Are Covering This

Bispecific antibodies transformed hematology and are now generating Phase 2 and 3 data in solid tumors at ASCO 2026. The tumor microenvironment presents a distinct biology challenge that is defining which engineering formats have a future outside hematology.

What to Expect

You will understand the engineering differences between bispecific formats, why solid tumor biology demands a different development approach, and how this pipeline positions relative to checkpoint inhibitors as the next immunotherapy platform.

Be first when this report publishes

The Life Science Feed briefing covers every major trial readout, approval, and pipeline shift, weekly.

Get the briefing first

thelifesciencefeed.com · Special Report

SR-2026-02007/26

Solid Tumors

Bowhead Whale Longevity Genes Offer Clues for Cancer, Aging

Insights from the bowhead whale's exceptional lifespan and cancer resistance point to novel genetic pathways for human anti-aging and oncology research.

Prostatic Neoplasms

Prostate Care: Balancing Immediate Relief with Long-Term Retreatment

Managing benign prostatic hyperplasia requires weighing rapid symptom improvement against the need for future interventions. Clinicians must consider patient preference and disease progression.

Breast Neoplasms

Genetic Test Identifies Breast Cancer Patients Who May Avoid Chemotherapy

A genetic test can identify patients with early-stage, hormone receptor-positive, HER2-negative breast cancer who may safely forgo adjuvant chemotherapy.

Breast Neoplasms

Giredestrant Improves Breast Cancer Survival Regardless of Menopause

Giredestrant, an oral selective estrogen receptor degrader (SERD), demonstrated improved invasive disease-free survival in early breast cancer.

Bispecific Antibodies Beyond Hematology: Solid Tumors Enter the Arena

Bispecific Antibodies Beyond Hematology: Solid Tumors Enter the Arena

Be first when this report publishes

Related Articles